| Business Summary |
| A biotechnology company, which is focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. |
| General Information |
3005 First Avenue
Seattle, WA 98121
|
| www.dendreon.com |
| Industry : Drugs |
| Sector: Health Care |
| Employees: 198 |
| CEO: Dr. Mitchell H. Gold, M. |
| Short Interest |
| Current Month (Mil) |
9.11 |
| Previous Month (Mil) |
8.43 |
| Short Interest Ratio (Days) |
3.60 |
| Management Effectiveness |
| Return on Equity |
N.A. |
| Return on Assets |
-55.40 |
| Return on Investments |
-105.00 |
| Profitability |
| Gross Margin |
N.A. |
| EBIT Margin |
N.A. |
| Profit Margin |
0.00 |